AYURVEDIC MANAGEMENT OF DYSLIPIDEMIA THROUGH VADAVANALA RAS: A CASE SERIES WITH NETWORK PHARMACOLOGY INSIGHTS

Dyslipidemia, a highly prevalent metabolic abnormality, significantly contributes to coronary artery disease and with its increasing global burden, necessitates early detection and targeted treatment. Aim/Objectives: To evalu-ate the clinical efficacy of Vadavanala Ras in the management of Dyslipidemia, explained through the Ayurve-dic concept of Medoroga and supported by network pharmacology, through a case series of patients with varia-ble lipid abnormalities. Materials and Methods: Three patients presenting with Dyslipidemia were assessed using Subjective and Objective parameters. Each patient received Vadavanala Ras (125 mg once daily after din-ner) with dietary modifications. Lipid profiles were recorded before and after one month of treatment. Network Pharmacology analysis was performed using databases such as IMPPAT, SwissTargetPrediction, and KEGG pathways to identify molecular targets of key ingredients in Vadavanala ras. Results: Across the series, patients showed significant improvement in lipid profiles. Total Cholesterol decreased by 17–26%, Triglycerides by 5–62%, LDL by 20–23%, while HDL increased by 21–37%. Network Pharmacology analysis revealed interactions with key Dyslipidemia-associated proteins, including JAK1, MTOR, AGTR1, PRKACA, STAT3, CYP17A1, etc., suggesting multi-target lipid-lowering and metabolic regulatory effects. Additionally, patients reported relief from musculoskeletal stiffness and neuromuscular pain, indicating broader systemic benefits. Conclusion: Va-davanala Ras demonstrated promising effects on lipid profiles in Dyslipidemia patients, with varied responses among patients. Network pharmacology supported its multi-target action and highlighted the relevance of classi-cal Ayurvedic formulations in metabolic care.